艾地苯醌对帕金森病患者非运动状态及miR-486-5p、miR-221的影响

Effects of Idbenone on Non-motor Status and miR-486-5p and miR-221 in Patients with Parkinson's Disease

目的探讨艾地苯醌对帕金森病患者非运动状态及miR-486-5p、miR-221的影响。方法选取2020年1月—2021年5月于郑州市中心医院收治的94例帕金森病患者,依据随机数表法将患者分为观察组和对照组,对照组(n=47)给予美多芭口服治疗,观察组(n=47)在对照组的基础上给予艾地苯醌口服治疗,治疗12周后比较2组患者临床疗效、非运动状态非运动症状评价量表、步态状态、脑神经递质(去甲肾上腺素、多巴胺及5-羟色胺)、miR-486-5p、miR-221表达等。结果观察组患者临床总有效率高于对照组(70.21%vs 42.55%)(χ^(2)=7.311,P=0.007);与对照组治疗后比较,观察组患者非运动状态严重程度与发生频率评分更低(P<0.05);观察组患者治疗后步长增加长度长于对照组(P<0.05),观察组患者治疗后步速及步频低于对照组(P<0.05);观察组患者去甲肾上腺素、多巴胺及5-羟色胺水平高于对照组(P<0.05);治疗后,观察组患者miR-486-5p水平高于对照组,miR-221水平低于对照组(P<0.05)。结论对于帕金森病患者选择艾地苯醌治疗能上调miR-486-5p水平表达,抑制miR-221表达,改善脑神经递质水平,从而改善患者的非运动症状、步态。

OBJECTIVE To explore the effect of idbenone on non-motor status,miR-486-5p and miR-221 in patients with Parkinson's disease.METHODS Ninety-four patients with Parkinson's disease admitted to Zhengzhou Central Hospital from January 2020 to May 2021 were selected and divided into observation group and control group according to random number table method.The control group(n=47)received oral treatment of metoba,and the observation group(n=47)received oral treatment of idbenone on the basis of the control group.After 12 weeks of treatment,clinical efficacy,non-motor status,gait status,brain neurotransmitters(norepinephrine,dopamine and serotonin),miR-486-5p and miR-221 expression were compared between the two groups.RESULTS The total effective rate of the observation group was higher than that of the control group(70.21%vs 42.55%)(x^(2)=7.311,P=0.007).Compared with the control group after treatment,the severity and frequency scores of non-exercise state in the observation group were lower(P<0.05).The length of step increase after treatment in observation group was longer than that in control group(P<0.05),and the step speed and step frequency of observation group were lower than that of control group(P<0.05).The levels of norepinephrine,dopamine and 5-hydroxyserotonin in observation group were higher than those in control group(P<0.05).After treatment,the level of miR-486-5p in observation group was higher than that in control group,and the level of miR-221 was lower than that in control group(P<0.05).CONCLUSION For patients with Parkinson's disease,idbenquinone can up-regulate the expression level of miR-486-5p,suppress the expression of miR-221,improve the level of brain neurotransmitters,and thus improve the non-motor symptoms and gait of patients.